Bone metabolism Product details
| Productname |
PYD Serum (Quidel®) |
|
Pyridinoline Crosslinks
Free PYD is measured |
| Cat-No. |
8019 |
|
4824 PYD Control (Serum) Set of 4 x 0.5 ml (4 levels)
Average: 1, 2, 4, 8 nmol/l |
| Range |
0.75 - 12 nmol/l |
| Sensitivity |
0.4 nmol/l |
| Incubation time |
26 hours |
| Sample volume |
200 µl |
| Sample type |
Serum |
| Sample preparation |
Keep specimens at 2-8°C for a maximum of 4 days or at -20°C for longer storage. No more than 3 freeze/thaw cycles. Filter samples by adding 200 µl to a 30kMWCO Spin filter. Centrifuge 30 minutes at 3,000-10,000 x g. Protect filtrate from exposure to light. |
| Reference values |
| |
(nmol/l) |
S.D. (nmol/l) |
| Premenopausal women (25 - 44 years) |
1.55 |
0.26 |
| Men (25 - 55 years) |
1.59 |
0.38 |
Reference values from children are available.
|
| Species |
Human, baboon, cat, bovine, dog, guinea pig, horse, rhesus macaque, mouse, rat, sheep |
| Cross reaction |
No cross reaction with free DPD, < 2.5 % with PYD/ DPD peptides |
| Tests |
96 Tests |
| Method |
ELISA |
| Product informations |
- Kit Instructions (pdf-File 211 kb)
- Children reference Values (pdf-File 400 kb)
- Cross-reaction all species (pdf-File 71 kb)
- Cell culture (pdf-File 93 kb)
- Bone & Cartilage Metabolism (pdf-File 2,480 kb)
|
| Intended use |
When bone or cartilage collagen is degraded, PYD is released into circulation and excreted in the urine. Deoxypyridinoline (DPD), a pyridinium crosslink differing from PYD only by the absence of an hydroxyl group, is essentially bone specific. The ratio of PYD:DPD in bone of approximately 4:1 is closely concordant with the ratio observed in urine of healthy individuals and those with metabolic bone diseases or osteoarthritis in spite of a much higher PYD:DPD ratio in non-bone tissues. In rheumatoid arthritis, destruction of cartilage and other collagen-containing joint tissue may contribute to increased levels of PYD.
Pyridinoline crosslinks are indicators for type-I collagen resorption, particularly for bone collagen. |
 Back to overview print view |
 |
|
